Making a case for del(1p) as a high-risk abnormality in multiple myeloma

被引：1
|
作者：
Schmidt, Timothy M. M. [1 ,2 ]
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[2] 600 Highland Ave,K6-544 MC 5669 Clin Sci Ctr, Madison, WI 53792 USA
来源：
CANCER | 2023年 / 129卷 / 16期
关键词：
PROGNOSTIC-FACTOR; DELETIONS; THERAPY; CDKN2C; GENES; 1P;
D O I：
10.1002/cncr.34893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2450 / 2452
页数：3
相关论文
共 50 条
  • [41] Treatment options for multiple myeloma patients with high-risk disease
    Ailawadhi, Sikander
    Masood, Aisha
    Sher, Taimur
    Miller, Kena C.
    Wood, Margaret
    Lee, Kelvin
    Chanan-Khan, Asher
    MEDICAL ONCOLOGY, 2010, 27 : 53 - 61
  • [42] Genomic characterization of functional high-risk multiple myeloma patients
    Soekojo, Cinnie Yentia
    Chung, Tae-Hoon
    Furqan, Muhammad Shaheryar
    Chng, Wee Joo
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [43] Myc rearrangement redefines the stratification of high-risk multiple myeloma
    Jin, Xianghong
    Li, Hui
    Zhang, Dingding
    Liu, Shuangjiao
    Song, Yuhang
    Zhang, Fujing
    Li, Ziping
    Zhuang, Junling
    CANCER MEDICINE, 2024, 13 (11):
  • [44] Erratum: A gene expression signature for high-risk multiple myeloma
    R Kuiper
    A Broyl
    Y de Knegt
    M H van Vliet
    E H van Beers
    B van der Holt
    L el Jarari
    G Mulligan
    W Gregory
    G Morgan
    H Goldschmidt
    H M Lokhorst
    M van Duin
    P Sonneveld
    Leukemia, 2014, 28 : 1178 - 1180
  • [45] Healthcare reality of the treatment of the high-risk multiple myeloma in Spain
    Hernandez-Rivas, Jose-Angel
    Gironella Mesa, Mercedes
    MEDICINA CLINICA, 2020, 154 (08): : 315 - 319
  • [46] Treatment options for multiple myeloma patients with high-risk disease
    Sikander Ailawadhi
    Aisha Masood
    Taimur Sher
    Kena C. Miller
    Margaret Wood
    Kelvin Lee
    Asher Chanan-Khan
    Medical Oncology, 2010, 27 : 53 - 61
  • [47] Genomic profiling of treated high-risk smoldering multiple myeloma
    Diamond, Benjamin
    Kazandjian, Dickran
    Papadimitriou, Marios
    Ziccheddu, Bachisio
    Blaney, Patrick
    Chojnacka, Monika
    Durante, Michael
    Hill, Elizabeth
    Sklavenitis-Pistofidis, Romanos
    Davies, Faith
    Getz, Gad
    Ghobrial, Irene
    Morgan, Gareth
    Maura, Francesco
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S227 - S228
  • [48] High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?
    Paszekova, Helena
    Kryukov, Fedor
    Kubiczkova, Lenka
    Hajek, Roman
    Sevcikova, Sabina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01): : 24 - 30
  • [49] Evolutionary dynamics and optimal management of high-risk multiple myeloma
    Shain, Kenneth
    Khin, Zayar
    Silva, Ariosto
    CLINICAL CANCER RESEARCH, 2015, 21
  • [50] Multiple myeloma with high-risk cytogenetics and its treatment approach
    Ichiro Hanamura
    International Journal of Hematology, 2022, 115 : 762 - 777
12345